| 產品名稱 |
F3B6 |
| 商品貨號 |
B164428 |
| Organism |
human (B cell); mouse (myeloma) |
| Cell Type |
hybridoma: B lymphocyte |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Applications |
The cells are resistant to 6-thioguanine. This line is suitable for fusing to human B cells for the production of human monoclonal antibodies. |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Derivation |
This line is suitable for fusing to human B cells for the production of human monoclonal antibodies. |
| Comments |
Fusion of human peripheral blood B cell with NS-1 myeloma cells. The cells are resistant to 6-thioguanine. This line is suitable for fusing to human B cells for the production of human monoclonal antibodies. |
| Complete Growth Medium |
Culture Medium: HL-1 medium, 99%; fetal bovine serum, 1%. Iscove's modified
Dulbecco's medium with 10% fetal bovine serum has been used as an alternative
to HL-1. |
| Subculturing |
Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 5 X 10 exp4 cells/ml and maintain between 5 X 10 exp4 and 1 X 10 exp6 cells/ml. |
| Cryopreservation |
HL-1 medium, 82.5%, human serum albumin, 10%; DMSO, 7.5% |
| Name of Depositor |
Cetus Corp. |
| Deposited As |
human (B cell); mouse (myeloma) |
| U.S. Patent Number |
|
| References |
Larrick JW, Raubitschek AA. Pseudomonas aeruginosa exotoxin A antibodies, their preparation and use. US Patent 4,677,070 dated Jun 30 1987
|
